ImmunityBio received FDA approval for ANKTIVA plus BCG for BCG-unresponsive bladder cancer in April. The drug has a unique mechanism of action. Immunity's early launch progress of Anktiva shows ...
I assigned a Hold rating to ImmunityBio, Inc. (IBRX) stock back in September last year in a note for Seeking Alpha, and prior to that, a Hold rating in April 2025, and a Buy rating in December 2024.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results